Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.49 |
| ▸ | TNNI3K | Q59H18 | 10/20 | 0.46 |
| ▸ | EGFR | P00533 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 3/20 | 0.44 |
| ▸ | CA12 | O43570 | 2/20 | 0.44 |
| ▸ | CA1 | P00915 | 2/20 | 0.44 |
| ▸ | CA2 | P00918 | 2/20 | 0.44 |
| ▸ | CA9 | Q16790 | 2/20 | 0.44 |
| ▸ | NAT1 | P18440 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | PTBP1 | P26599 | 1/20 | 0.41 |
| ▸ | CA3 | P07451 | 1/20 | 0.41 |
| ▸ | CA4 | P22748 | 1/20 | 0.41 |
| ▸ | CA6 | P23280 | 1/20 | 0.41 |
| ▸ | CA5A | P35218 | 1/20 | 0.41 |
| ▸ | CA7 | P43166 | 1/20 | 0.41 |
| ▸ | CA13 | Q8N1Q1 | 1/20 | 0.41 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2242660 | 0.82 | L3MBTL1 (0.61) | L3MBTL1TNNI3KEGFRLMNACA12 | |
| SCHEMBL24226848 | 0.82 | CA12 (0.49) | L3MBTL1TNNI3KEGFRCA12CA1 | |
| SCHEMBL941584 | 0.81 | CA12 (0.44) | LMNACA12CA1CA2CA9 | |
| SCHEMBL14674169 | 0.81 | KMT2A (0.47) | TNNI3KLMNACA12CA1CA2 | |
| SCHEMBL2854486 | 0.81 | MAPT (0.65) | LMNACA12CA1CA2CA9 | |
| SCHEMBL14674759 | 0.81 | ALDH1A1 (0.44) | CA12CA1CA2CA9NAT1 | |
| SCHEMBL15652008 | 0.79 | LMNA (0.66) | LMNACA1CA2ALDH1A1PTBP1 | |
| SCHEMBL41941 | 0.79 | CA12 (0.47) | CA12CA1CA2CA9NAT1 | |
| SCHEMBL30402657 | 0.79 | CA12 (0.47) | CA12CA1CA2CA9NAT1 | |
| SCHEMBL14674435 | 0.78 | KMT2A (0.53) | LMNACA12CA1CA2CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9637491-B2 | Pyrazolo[4,3-D]pyrimidines as kinase inhibitors | ORIGENIS GMBH (DE) | 2017-05-02 | — | — | US | disclosed |
| US-20150266882-A1 | PYRAZOLO[4,3-D]PYRIMIDINES AS KINASE INHIBITORS | ORIGENIS GMBH (DE) | 2015-09-24 | — | — | US | disclosed |
| US-8877946-B2 | Benzylidene-indolinone compounds and their medical use | NATIONAL UNIVERSITY OF SINGAPORE (SG) | 2014-11-04 | — | — | US | disclosed |
| US-8877946-B2 | Benzylidene-indolinone compounds and their medical use | NATIONAL UNIVERSITY OF SINGAPORE (SG) | 2014-11-04 | — | — | US | disclosed |
| US-8877946-B2 | Benzylidene-indolinone compounds and their medical use | NATIONAL UNIVERSITY OF SINGAPORE (SG) | 2014-11-04 | — | — | US | disclosed |
| WO-2014060112-A1 | PYRAZOLO[4,3-D]PYRIMIDINES AS KINASE INHIBITORS | ORIGENIS GMBH (DE) | 2014-04-24 | — | — | WO | disclosed |
| US-20130035364-A1 | BENZYLIDENE-INDOLINONE COMPOUNDS AND THEIR MEDICAL USE | NATIONAL UNIVERSITY OF SINGAPORE (SG) | 2013-02-07 | — | — | US | disclosed |
| US-20130035364-A1 | BENZYLIDENE-INDOLINONE COMPOUNDS AND THEIR MEDICAL USE | NATIONAL UNIVERSITY OF SINGAPORE (SG) | 2013-02-07 | — | — | US | disclosed |
| US-20130035364-A1 | BENZYLIDENE-INDOLINONE COMPOUNDS AND THEIR MEDICAL USE | NATIONAL UNIVERSITY OF SINGAPORE (SG) | 2013-02-07 | — | — | US | disclosed |
| US-5037824-A | Cardiotonic, antiischemic agents | FUJISAWA PHARMACEUTICAL COMPANY, LTD. (JP) | 1991-08-06 | — | — | US | disclosed |
| EP-0387070-A2 | N-Containing heterocyclic compounds, processes for the preparation thereof and composition comprising the same | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1990-09-12 | — | — | EP | disclosed |
| US-3931142-A | Heterocyclic containing disazo compounds | CIBA-GEIGY AG (CH) | 1976-01-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150266882-A1 | PYRAZOLO[4,3-D]PYRIMIDINES AS KINASE INHIBITORS | LRRK2, MYLK2, MYLK | L3MBTL1 505/4885TNNI3K 129/4885EGFR 901/4885 |
| US-20130035364-A1 | BENZYLIDENE-INDOLINONE COMPOUNDS AND THEIR MEDICAL USE | ERBB2, ABL1, IGF1R | L3MBTL1 1969/4885TNNI3K 80/4885EGFR 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.